You just read:

Resolution Bioscience's ctDx™ Blood-based NGS Platform used for Plasma Genotyping and Longitudinal Monitoring of ALK Fusion Positive Patients in Clinical Trial

News provided by

Resolution Bioscience

Jun 01, 2016, 06:00 ET